Evidence map›Paper›PMID 42535495›Full record

ArticleChemMedChem2026

Heavy-Atom-Free Dual-Action Dual PACT/PDT action Pt(IV) Prodrug With BODIPY Dimer in Axial Position.

Vladislav Bykusov, Yulia Isaeva, Roman Akasov, Tatiana Egorova, Valerii Mun, Dmitry Bunin, Vladimir Kuzmin, Anton Egorov, Ivan Burtsev, Yuri Grishin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vladislav BykusovChemistry Department, Lomonosov Moscow State University, Moscow, Russia.
Yulia IsaevaChemistry Department, Lomonosov Moscow State University, Moscow, Russia.
Roman AkasovEnikolopov Institute of Synthetic Polymer Materials RAS, Moscow, Russia.
Tatiana EgorovaDepartment of Bioсhemistry, Petrovsky Medical University, Moscow, Russia.
Valerii MunN.K. Koltsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia.ORCID https://orcid.org/0009-0005-8299-9595
Dmitry BuninFrumkin Institute of Physical Chemistry and Electrochemistry Russian Academy of Sciences, Moscow, Russia.ORCID https://orcid.org/0000-0002-1312-4016
Vladimir KuzminEmanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia.
Anton EgorovEmanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia.
Ivan BurtsevEmanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia.
Yuri GrishinChemistry Department, Lomonosov Moscow State University, Moscow, Russia.
Igor RodinChemistry Department, Lomonosov Moscow State University, Moscow, Russia.
Mikhail VokuevChemistry Department, Lomonosov Moscow State University, Moscow, Russia.
Elena BeloglazkinaChemistry Department, Lomonosov Moscow State University, Moscow, Russia.ORCID https://orcid.org/0000-0001-6796-8241
Olga KrasnovskayaChemistry Department, Lomonosov Moscow State University, Moscow, Russia.ORCID https://orcid.org/0000-0002-4948-2747

Funding

Russian Science Foundation 22-15-00182-П
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a clinically approved therapeutic modality with great potential for the treatment of cancers due to its excellent spatiotemporal selectivity and noninvasivenes. A combination of light-controlled chemotherapy (PACT) and PDT in one molecule has the potential to overcome crucial drawbacks of both Pt-based chemotherapy and PDT via a synergetic effect. Herein, we report a Pt(IV)-BODIPY agent for dual light-controlled chemophotodynamic therapy, a Pt(IV) prodrug with a BODIPY orthogonal dimer in the axial position. The orthogonal arrangement of the fluorophores results in a long-lived, "heavy-atom-free" triplet state of the dimeric fluorophore. The high quantum yield of singlet oxygen for the dimer fluorophore and the Pt(IV) prodrug based on it was confirmed, and the formation of the triplet state was demonstrated by flash photolysis. The excellent photosensitive properties of the Pt(IV) prodrug on SK-BR-3 and MCF-7 tumor cells demonstrate photocontrolled toxicity and potential for the development of dual therapy conjugates.

Indexed as

Antineoplastic AgentsBoron CompoundsOrganoplatinum CompoundsPhotochemotherapyPhotosensitizing AgentsProdrugsCell Line, TumorCell ProliferationCell SurvivalDimerizationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansLightMCF-7 CellsMolecular Structure4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneAntineoplastic AgentsBoron CompoundsOrganoplatinum CompoundsPhotosensitizing AgentsProdrugsSinglet Oxygenboron dipyrromethenecisplatinphotoactivationphotodynamic therapyprodrug

Identifiers

PMID42535495
PMCPMC13425680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.